Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cancer therapies and diagnostics group Avacta reported deeper first-half losses as higher research and development costs offset a rise in revenue.
For the six-month period ended 30 June 2020, pre-tax losses widened to £8.1 million from £6.6 million year-on-year while revenues increased to £1.8 million from £1.1 million
Research and amortisation of development costs increased to £4.2 million from £2.9 million.
'We have several momentous milestones ahead of us with the anticipated launch of a rapid, saliva based coronavirus antigen lateral flow test and the planned phase I study for AVA6000 pro-doxorubicin, the first pre|CISION pro-drug,' the company said.
'The recent placing has also allowed us to resource an expanded Affimer immunotherapy and pre|CISION chemotherapy pipeline and substantially increase the size of the research and clinical development teams at our Cambridge site to deliver on this.'
At 9:19am: (LON:AVCT) Avacta Group PLC share price was -17p at 149p